MELISSA CETAK: Open Payments
NPI 1588654842 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,301 in 63 payments from 32 companies in 2025. Trend: 2023 $1,472 · 2024 $1,336 · 2025 $1,301
Food & beverage: $1,111Education: $190
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $108 |
| ABBVIE INC. | 4 | $100 |
| SEAGEN INC. | 1 | $100 |
| SANOFI-AVENTIS U.S. LLC | 1 | $90 |
| PFIZER INC. | 6 | $83 |
| E.R. Squibb & Sons, L.L.C. | 4 | $68 |
| Eisai Inc. | 3 | $66 |
| Celgene Corporation | 3 | $50 |
| Adaptive Biotechnologies Corporation | 3 | $49 |
| Ipsen Biopharmaceuticals, Inc | 2 | $48 |
Products named: SARCLISA, OPDUALAG, Lenvima, SCEMBLIX, EPKINLY, REBLOZYL, clonoSEQ, Onivyde.
Industry payments across NE — which companies pay providers there.
